|

ipilimumab +pembrolizumab +durvalumab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Second Affiliated Hospital of Guangzhou Medical University1

Indications

  • Liver Disease1
  • Ovary Cancer1
  • Pancreas Cancer1
  • Sarcoma1
  • Head and Neck Cancer1

Other1 trial

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.